SEARCH

SEARCH BY CITATION

References

  • 1
    Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713723.
  • 2
    Rush DN, Nickerson P, Gough J et al. Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 1998; 9: 21292134.
  • 3
    Nickerson P, Jeffery JR, Gough J et al. Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: A pilot study. J Am Soc Nephrol 1999; 10: 18011805.
  • 4
    Jurewicz WA. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: An interim report. Transplant Proc 1993; 31(Supp 7A): S64S66.
  • 5
    Shapiro R, Randhawa P, Jordan ML et al. An analysis of early renal transplant protocol biopsies—the high incidence of subclinical tubulitis. Am J Transplant 2001; 1: 4750.
  • 6
    Nankivell BJ, Borrows RJ, Fung CLS, O’Connell PJ, Allen RDM, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in renal transplantation. Transplantation 2004; 78: 242249.
  • 7
    Gloor JM, Cohen AJ, Lager DJ et al. Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation 2002; 73: 19651968.
  • 8
    Moreso F, Serón D, Carrera M et al. Baseline immunosuppression is associated with histological findings in early protocol biopsies. Transplantation 2004; 78: 10641068.
  • 9
    Rowshani AT, Scholten EM, Bemelman F et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol 2006; 17: 305312.
  • 10
    Schwarz A, Mengel M, Gwinner W et al. Risk factors for chronic allograft nephropathy after renal transplantation: A protocol biopsy study. Kidney Int 2005; 67: 341348.
  • 11
    Nickerson P, Jeffery JR, Gough J et al. Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol 1998; 9: 482487.
  • 12
    Legendre C, Thervet E, Skhiri H et al. Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation 1998; 65: 15061509.
  • 13
    Nankivell BJ, Fenton-Lee CA, Kuypers DR et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71: 515523.
  • 14
    Serón D, Moreso F, Bover J et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 51: 310316.
  • 15
    Auphan N, DiDonato JA, Rosette C, Helberg A, Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-κB activation through induction of IF-κB synthesis. Science 1995; 270: 286290.
  • 16
    Laftavi M, Stephan R, Stefanick B et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005; 137: 364371.
  • 17
    Schrier RW, Burk TJ. Role of calcium-channel blockers in preventing acute and chronic renal injury. J Cardiovasc Pharmacol 1991; 18(Suppl 6): S38S43.
  • 18
    Ruggenenti P, Perico N, Mosconi L et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43: 706711.
  • 19
    Kuypers DRJ, Neumayer HH, Fritsche L, Budde K, Rodicio JL, Vanrenterghem Y. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: A prospective randomized placebo controlled 2-year study. Transplantation 2004; 78: 12041211.
  • 20
    Klein IH, Abraham A, Van Ede T, Hene RJ, Koomans HA, Ligtenberg G. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 732736.
  • 21
    Nankivell BJ, Chapman JR, Bonovas G, Gruenwald SM. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 2004; 77: 14571459.
  • 22
    Grimm PC, Nickerson P, Gough J et al. Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 2003; 14: 16621668.
  • 23
    Encarnación MM, Griffin MD, Slezak JM et al. Correlation of quantitative digital image with the glomerular filtration rate in chronic allograft nephropathy. Am J Transplant 2003; 4: 248256.
  • 24
    Rostaing L, Cantarovitch D, Mourad G et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807814.
  • 25
    Furness PN, Philpott CM, Chorbadjian MT et al. Protocol biopsy of the stable renal transplant: A multicenter study of methods and complication rates. Transplantation 2003; 76: 909910.
  • 26
    Schwarz A, Gwinner W, Hiss M, Radermacher J, Mengel M, Haller H. Safety and adequacy of protocol biopsies. Am J Transplant 2005; 5: 19921996.
  • 27
    Racusen LC. Protocol transplant biopsies in kidney allografts: Why and when are they indicated Clin J Am Soc Nephrol 2006; 1: 144147.